查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954240

凝血因子缺乏症市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、劑型、設備、解決方案分類

Coagulation Factor Deficiency Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Form, Device, Solutions
出版日期: | 出版商: Global Insight Services | 英文 372 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

凝血因子缺乏症市場預計將從2024年的55億美元成長到2034年的95億美元，複合年成長率約為6.6%。該市場涵蓋用於治療血液凝血因子缺乏症的產品和治療方法，這些凝血因子對於治療血友病和血管性血友病等出血性疾病至關重要。該市場包括重組和血漿來源的凝血因子濃縮物、基因療法和新型治療方法。公眾意識的提高、醫療技術的進步以及出血性疾病發病率的上升，以及對個人化醫療和改善患者預後的關注，都在推動市場成長。

凝血因子缺乏症市場預計將迎來顯著成長，這主要得益於治療方法的進步和人們對出血性疾病認知的提高。重組凝血因子濃縮物是該市場的主要驅動力，與血漿衍生產品相比，其安全性和有效性更高。在該細分市場中，因子VIII濃縮物的成長速度最快，滿足了A型血友病患者的需求；其次是因子IX濃縮物，主要針對B型血友病患者。預防性治療領域也表現強勁，反映出人們的治療理念正轉向以減少出血事件和提高患者生活品質為目標的預防性護理。隨著個人化醫療需求的不斷成長，基因療法已成為一個充滿前景的新領域。這項創新技術為凝血因子缺乏症提供了長期解決方案，並有望改變現有的治療模式。此外，旨在減少給藥頻率和提高患者依從性的半衰期延長產品的研發也正在加速推進。這些趨勢凸顯了市場的動態發展，並為相關人員帶來了盈利的機會。

市場區隔
按類型 A型血友病A、B型血友病、血管性血友病、凝血因子II缺乏症、凝血因子V缺乏症、凝血因子VII缺乏症、凝血因子X缺乏症、凝血因子XI缺乏症、凝血因子XIII缺乏症
產品 血漿來源的凝血因子、重組凝血因子
服務 診斷、諮詢和治療服務
科技 基因療法、蛋白質替代療法
適用的 預防、按需治療和手術
最終用戶 醫院、專科診所和居家醫療機構
形式 注射劑和口服藥物
醫療設備 輸液裝置、監測裝置
解決方案 患者管理、庫存管理

凝血因子缺乏症市場瞬息萬變，市佔率和定價策略不斷發生顯著變化。主要企業正積極推出創新產品，旨在滿足未被滿足的需求並改善患者預後。這些策略性產品發布正在重塑市場競爭格局，並拓展治療選擇。定價競爭異常激烈，並受到區域市場需求和醫療政策的影響，而這些因素對於患者的可及性和負擔能力至關重要。競爭基準分析顯示，老牌製藥巨頭和新興生技公司都在積極爭奪市場主導地位。監管的影響，尤其是在北美和歐洲，透過制定核准流程和合規標準，對市場動態的形成起著至關重要的作用。該市場的特點是高度重視研發投入，以提高治療效果和安全性。在不斷變化的監管環境下，各公司正在策略性地調整產品系列，以滿足嚴格的指導方針，並實現永續成長和市場滲透。先進技術和個人化醫療方法的整合有望進一步推動市場擴張。

主要趨勢和促進因素：

凝血因子缺乏症市場正經歷顯著擴張，主要得益於多項新興趨勢和促進因素。其中一個關鍵趨勢是全球出血性疾病盛行率的不斷上升，因此需要更先進的治療方案。診斷能力的提升和公眾意識的增強推動了這一成長，使得早期發現和早期療育成為可能。此外，重組DNA技術的重大進步也促進了創新有效治療方法的研發。另一個關鍵趨勢是個人化醫療的日益普及，這使得客製化治療方案成為可能，從而改善患者的治療效果。居家醫療模式也正在蓬勃發展，為患者提供更多便利並降低醫療成本。推動該市場成長的因素包括全球人口老化，導致更多人容易罹患凝血障礙，以及醫療基礎設施投資的不斷增加。此外，政府為改善罕見疾病治療可及性而採取的措施也促進了市場成長。新興經濟體及其正在發展的醫療體系為市場提供了許多進入機會。專注於研發和策略合作的公司將更有利於掌握這些機遇，並在凝血因子缺乏症市場實現持續成長和創新。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • A型血友病A
    • B型血友病
    • 血管性血友病
    • 因子 II 缺乏症
    • V 因子缺乏症
    • 因子VII缺乏症
    • X因子缺乏症
    • 因子XI缺乏症
    • 因子 XIII 缺乏症
  • 市場規模及預測：依產品分類
    • 血漿衍生凝血因子
    • 重組凝血因子
  • 市場規模及預測：依服務分類
    • 診斷服務
    • 諮詢服務
    • 治療服務
  • 市場規模及預測：依技術分類
    • 基因治療
    • 蛋白質替代療法
  • 市場規模及預測：依應用領域分類
    • 預防性治療
    • 按需治療
    • 外科手術
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 居家醫療環境
  • 市場規模及預測：依類型
    • 注射
    • 口服
  • 市場規模及預測：依設備分類
    • 點滴裝置
    • 監控設備
  • 市場規模及預測：按解決方案分類
    • 病患管理
    • 庫存管理

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Octapharma
  • CSL Behring
  • Kedrion Biopharma
  • Grifols
  • Sobi
  • LFB Group
  • Bio Products Laboratory
  • Sanquin
  • Green Cross Corporation
  • Shanghai RAAS Blood Products
  • Baxter International
  • Biotest AG
  • Hualan Biological Engineering
  • Shire
  • Pfizer
  • Novo Nordisk
  • Bayer Healthcare
  • Takeda Pharmaceutical
  • Ferring Pharmaceuticals
  • Sanofi Genzyme

第9章：關於我們

簡介目錄
Product Code: GIS26274

Coagulation Factor Deficiency Market is anticipated to expand from $5.5 billion in 2024 to $9.5 billion by 2034, growing at a CAGR of approximately 6.6%. The Coagulation Factor Deficiency Market encompasses products and therapies addressing deficiencies in blood clotting factors, critical for managing bleeding disorders like hemophilia and von Willebrand disease. This market includes recombinant and plasma-derived factor concentrates, gene therapies, and novel treatment approaches. Increasing awareness, advancements in medical technology, and rising incidence of bleeding disorders propel market growth, with a focus on personalized medicine and improved patient outcomes.

The Coagulation Factor Deficiency Market is poised for substantial growth, driven by advancements in treatment options and increasing awareness of bleeding disorders. The recombinant coagulation factor concentrates segment leads the market, offering enhanced safety and efficacy over plasma-derived products. Among these, Factor VIII concentrates are the top-performing sub-segment, addressing the needs of Hemophilia A patients. Factor IX concentrates follow closely, serving the Hemophilia B population. The prophylaxis treatment segment also exhibits strong performance, reflecting a shift towards preventive care to reduce bleeding episodes and improve patient quality of life. Demand for personalized medicine is rising, with gene therapy emerging as a promising frontier. This innovation aims to offer long-term solutions for coagulation deficiencies, potentially transforming treatment paradigms. Furthermore, the development of extended half-life products is gaining momentum, aiming to reduce the frequency of administration and enhance patient adherence. These trends underscore the market's dynamic evolution and lucrative opportunities for stakeholders.

Market Segmentation
TypeHemophilia A, Hemophilia B, Von Willebrand Disease, Factor II Deficiency, Factor V Deficiency, Factor VII Deficiency, Factor X Deficiency, Factor XI Deficiency, Factor XIII Deficiency
ProductPlasma-derived Coagulation Factors, Recombinant Coagulation Factors
ServicesDiagnostic Services, Consultation Services, Therapeutic Services
TechnologyGene Therapy, Protein Replacement Therapy
ApplicationProphylaxis, On-demand Treatment, Surgery
End UserHospitals, Specialty Clinics, Homecare Settings
FormInjectables, Oral
DeviceInfusion Devices, Monitoring Devices
SolutionsPatient Management, Inventory Management

The Coagulation Factor Deficiency Market is witnessing a dynamic landscape with significant shifts in market share and pricing strategies. Key players are actively launching innovative products, aiming to address unmet medical needs and improve patient outcomes. These strategic introductions are reshaping competitive positioning and enhancing therapeutic options. Pricing remains competitive, influenced by regional market demands and reimbursement policies, which are pivotal in determining accessibility and affordability for patients. Competition benchmarking reveals a robust presence of established pharmaceutical giants alongside emerging biotechs, each vying for market dominance. Regulatory influences, particularly in North America and Europe, are critical in shaping market dynamics, dictating approval pathways and compliance standards. The market is characterized by a strong focus on R&D investments, driving advancements in treatment efficacy and safety. As regulatory landscapes evolve, companies are strategically aligning their portfolios to meet stringent guidelines, ensuring sustained growth and market penetration. The integration of advanced technologies and personalized medicine approaches is anticipated to further propel market expansion.

Geographical Overview:

The Coagulation Factor Deficiency Market is witnessing varied growth trajectories across regions. North America remains at the forefront, driven by advanced healthcare infrastructure and increased awareness of bleeding disorders. The presence of leading pharmaceutical companies further consolidates its position. Europe follows, with significant investments in research and development for innovative treatments, alongside favorable reimbursement policies supporting market growth. In Asia Pacific, the market is expanding rapidly due to rising healthcare expenditure and increased diagnosis rates of coagulation disorders. Emerging economies like China and India are pivotal, with growing investments in healthcare and expanding patient populations. Latin America is also gaining traction, with Brazil and Mexico showing promising growth due to improved healthcare access and government initiatives. The Middle East & Africa are nascent yet emerging markets, with increasing recognition of coagulation disorders and gradual improvements in healthcare infrastructure. These regions present untapped opportunities for market expansion and innovation in treatment modalities.

The Coagulation Factor Deficiency Market is intricately influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, strategies are increasingly geared towards enhancing domestic production capabilities to mitigate tariff-induced costs and geopolitical uncertainties. China is intensifying efforts to bolster its self-sufficiency in biopharmaceuticals amidst export restrictions, whereas Taiwan is leveraging its advanced biotech sector while navigating geopolitical tensions. The parent market is experiencing robust growth globally, driven by rising healthcare demands and technological advancements. By 2035, the market is poised for significant expansion, contingent upon strategic alliances and resilient supply chains. Furthermore, Middle East conflicts could indirectly affect this market by influencing global energy prices, thereby impacting manufacturing and distribution costs across the sector.

Key Trends and Drivers:

The Coagulation Factor Deficiency Market is experiencing notable expansion driven by several emerging trends and influential drivers. A primary trend is the increased prevalence of bleeding disorders worldwide, necessitating advanced treatment solutions. This surge is attributed to enhanced diagnostic capabilities and heightened awareness, prompting early detection and intervention. Additionally, the market is witnessing substantial advancements in recombinant DNA technology, leading to the development of innovative and effective therapies. Another significant trend is the growing inclination towards personalized medicine, allowing for tailored treatment regimens that enhance patient outcomes. The rise of homecare settings for administering treatments is also gaining momentum, offering convenience and reducing healthcare costs. Drivers of this market include the aging global population, which is more susceptible to coagulation disorders, and the increasing investment in healthcare infrastructure. Moreover, government initiatives aimed at improving access to treatment for rare diseases are fostering market growth. Opportunities abound in emerging economies where healthcare systems are evolving, presenting a fertile ground for market penetration. Companies focusing on research and development, along with strategic partnerships, are well-positioned to capitalize on these opportunities, ensuring sustained growth and innovation in the Coagulation Factor Deficiency Market.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Form
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Hemophilia A
    • 4.1.2 Hemophilia B
    • 4.1.3 Von Willebrand Disease
    • 4.1.4 Factor II Deficiency
    • 4.1.5 Factor V Deficiency
    • 4.1.6 Factor VII Deficiency
    • 4.1.7 Factor X Deficiency
    • 4.1.8 Factor XI Deficiency
    • 4.1.9 Factor XIII Deficiency
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Plasma-derived Coagulation Factors
    • 4.2.2 Recombinant Coagulation Factors
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostic Services
    • 4.3.2 Consultation Services
    • 4.3.3 Therapeutic Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Therapy
    • 4.4.2 Protein Replacement Therapy
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Prophylaxis
    • 4.5.2 On-demand Treatment
    • 4.5.3 Surgery
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Specialty Clinics
    • 4.6.3 Homecare Settings
  • 4.7 Market Size & Forecast by Form (2020-2035)
    • 4.7.1 Injectables
    • 4.7.2 Oral
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Infusion Devices
    • 4.8.2 Monitoring Devices
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Patient Management
    • 4.9.2 Inventory Management

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Form
      • 5.2.1.8 Device
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Form
      • 5.2.2.8 Device
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Form
      • 5.2.3.8 Device
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Form
      • 5.3.1.8 Device
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Form
      • 5.3.2.8 Device
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Form
      • 5.3.3.8 Device
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Form
      • 5.4.1.8 Device
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Form
      • 5.4.2.8 Device
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Form
      • 5.4.3.8 Device
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Form
      • 5.4.4.8 Device
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Form
      • 5.4.5.8 Device
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Form
      • 5.4.6.8 Device
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Form
      • 5.4.7.8 Device
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Form
      • 5.5.1.8 Device
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Form
      • 5.5.2.8 Device
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Form
      • 5.5.3.8 Device
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Form
      • 5.5.4.8 Device
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Form
      • 5.5.5.8 Device
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Form
      • 5.5.6.8 Device
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Form
      • 5.6.1.8 Device
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Form
      • 5.6.2.8 Device
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Form
      • 5.6.3.8 Device
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Form
      • 5.6.4.8 Device
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Form
      • 5.6.5.8 Device
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Octapharma
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 CSL Behring
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Kedrion Biopharma
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Grifols
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Sobi
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 LFB Group
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bio Products Laboratory
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Sanquin
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Green Cross Corporation
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Shanghai RAAS Blood Products
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Baxter International
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Biotest AG
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Hualan Biological Engineering
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Shire
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pfizer
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Novo Nordisk
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bayer Healthcare
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Takeda Pharmaceutical
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Ferring Pharmaceuticals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Sanofi Genzyme
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us